An evaluation of the diagnostic value of FIB/PT ratio for patients with primary liver cancer
Xiao Ling1, Ran Songlin1, Bai Xiaoxia2, Lei Nana2, Chen Zhiyong1
1. Department of Gastroenterology, Suizhou Central Hospital (Suizhou Hospital Affiliated to Hubei University of Medicine), Suizhou 441300,China; 2. Suizhou Central Hospital (Suizhou Hospital Affiliated to Hubei University of Medicine), Suizhou 441300,China
Xiao Ling, Ran Songlin, Bai Xiaoxia, Lei Nana, Chen Zhiyong. An evaluation of the diagnostic value of FIB/PT ratio for patients with primary liver cancer[J]. Chinese Hepatolgy, 2026, 31(7): 971-974.
[1] 张丹霞,张永虎,桂若虎,等. 甲胎蛋白、甲胎蛋白异质体与肿瘤坏死因子α检测在原发性肝癌诊断中的应用价值[J]. 中国当代医药,2021,28(26):223-225,229. [2] 田州,张建淮. 甲胎蛋白诊断和筛查原发性肝癌的阈值分析[J]. 临床肝胆病杂志,2018,34(11):2352-2355. [3] 李正康,张鑫强,刘素玲,等. 凝血四项指标和肿瘤标志物在乙型肝炎病毒感染相关肝硬化和原发性肝癌中的诊断价值[J]. 中国实验诊断学,2016,20(12):2061-2065. [4] 曾灏,翚缨,覃文周,等. 凝血四项、PIVKA-Ⅱ、AFP三联诊断乙型肝炎相关肝癌的临床价值[J]. 吉林医学,2021,42(6):1455-1456. [5] Qi F, Zhou A, Yan L, et al.The diagnostic value of PIVKA-Ⅱ, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma[J]. J Clin Lab Anal, 2020 ,34(5):e23158. [6] Kim D Y, Toan B N, Tan C K, et al.Utility of combining PIVKA-Ⅱ and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region[J]. Clin Mol Hepatol,2023,29(2):277-292. [7] 栾珊,滕静,邵翠华. 甲胎蛋白异质体诊断原发性肝癌价值的Meta分析[J]. 青岛大学学报(医学版),2020,56(2):203-206. [8] Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma[J]. FEBS J,2013,280(10):2471-2476. [9] 王琴. 甲胎蛋白和血清异常凝血酶原联合检测对肝细胞癌的诊断价值[J]. 名医,2023(3):66-68. [10] Mao M, Wang X, Song Y, et al.Novel prognostic scores based on plasma prothrombin time and fibrinogen levels in patients With AFP-negative hepatocellular carcinoma[J]. Cancer Control,2020,27(1):1073274820915520. [11] 文夏杰. 术前凝血功能指标在原发性肝癌患者诊断及预后判断中的应用[D]. 郑州:郑州大学,2017.